Archive for 2014

Kinik: Raising the stakes for importing products derived from US patented processes practised abroad

Journal of Commercial Biotechnology
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Kinik: Raising the stakes for importing products derived from US patented processes practised abroad

Go to paper

ABSTRACT: This paper analyses the recent ruling in Kinik Co. v. Int’l Trade Comm’n, 362 F.3d 1359 (Fed. Cir. 2004), and the impact that decision may have on proceedings before the US International Trade Commission under the Tariff Act of 1930 (19 USC §1337(a)) – particularly those concerning the importation of products derived from practising US patented processes abroad.

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website


Drug Patent Expirations for December 7 2014

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Journal of Commercial Biotechnology

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for December 7 2014

Tradename Applicant Generic Name Patent
Expiration
NOVOLOG

Novo Nordisk Inc

insulin aspart recombinant

Dec 7, 2014
NOVOLOG FLEXPEN

Novo Nordisk Inc

insulin aspart recombinant

Dec 7, 2014
NOVOLOG FLEXTOUCH

Novo Nordisk Inc

insulin aspart recombinant

Dec 7, 2014
NOVOLOG INNOLET

Novo Nordisk Inc

insulin aspart recombinant

Dec 7, 2014
NOVOLOG MIX 50/50

Novo Nordisk Inc

insulin aspart protamine recombinant; insulin aspart
recombinant

Dec 7,
2014
NOVOLOG MIX 70/30

Novo Nordisk Inc

insulin aspart protamine recombinant; insulin aspart
recombinant

Dec 7,
2014
NOVOLOG MIX 70/30 FLEXPEN

Novo Nordisk Inc

insulin aspart protamine recombinant; insulin aspart
recombinant

Dec 7,
2014
NOVOLOG MIX 70/30 PENFILL

Novo Nordisk Inc

insulin aspart protamine recombinant; insulin aspart
recombinant

Dec 7,
2014
NOVOLOG PENFILL

Novo Nordisk Inc

insulin aspart recombinant

Dec 7, 2014

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch database for
complete details.





Instant Access to Deep Knowledge on Small-Molecule
Drugs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data
    export
  • More…

More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.

See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch database for
complete details

DISCLAIMER:
Although great care
is taken in the proper and correct provision of this service, thinkBiotech
LLC does not accept any responsibility for possible consequences of errors
or omissions in the provided information. There is no warranty that the
information contained herein is error free. Users of this service are
advised to seek professional advice and independent confirmation before
acting on any of the provided information. thinkBiotech LLC reserves the
right to amend, extend or withdraw any part or all of the offered service
without notice.
All trademarks and applicant names are the property
of their respective owners or licensors.


Drug Patent Expirations for December 3 2014

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

DrugPatentWatch -- sales, statistics, drug application information

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for December 3 2014

Tradename Applicant Generic Name Patent
Expiration
NORVIR

Abbott

ritonavir

Dec 3, 2014

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch database for
complete details.





Instant Access to Deep Knowledge on Small-Molecule
Drugs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data
    export
  • More…

More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.

See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch database for
complete details

DISCLAIMER:
Although great care
is taken in the proper and correct provision of this service, thinkBiotech
LLC does not accept any responsibility for possible consequences of errors
or omissions in the provided information. There is no warranty that the
information contained herein is error free. Users of this service are
advised to seek professional advice and independent confirmation before
acting on any of the provided information. thinkBiotech LLC reserves the
right to amend, extend or withdraw any part or all of the offered service
without notice.
All trademarks and applicant names are the property
of their respective owners or licensors.


Drug Patent Expirations for December 2 2014

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Journal of Commercial Biotechnology

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for December 2 2014

Tradename Applicant Generic Name Patent
Expiration
MYLOTARG

Wyeth Pharms Inc

gemtuzumab ozogamicin

Dec 2, 2014
TRAVATAN

Alcon Pharms Ltd

travoprost

Dec 2, 2014
TRAVATAN Z

Alcon Pharms Ltd

travoprost

Dec 2, 2014

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch database for
complete details.





Instant Access to Deep Knowledge on Small-Molecule
Drugs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data
    export
  • More…

More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.

See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch database for
complete details

DISCLAIMER:
Although great care
is taken in the proper and correct provision of this service, thinkBiotech
LLC does not accept any responsibility for possible consequences of errors
or omissions in the provided information. There is no warranty that the
information contained herein is error free. Users of this service are
advised to seek professional advice and independent confirmation before
acting on any of the provided information. thinkBiotech LLC reserves the
right to amend, extend or withdraw any part or all of the offered service
without notice.
All trademarks and applicant names are the property
of their respective owners or licensors.


Drug Patent Expirations for November 30 2014

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Journal of Commercial Biotechnology

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for November 30 2014

Tradename Applicant Generic Name Patent
Expiration
SULAR

Shionogi Inc

nisoldipine

Nov 30, 2014

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch database for
complete details.





Instant Access to Deep Knowledge on Small-Molecule
Drugs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data
    export
  • More…

More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.

See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch database for
complete details

DISCLAIMER:
Although great care
is taken in the proper and correct provision of this service, thinkBiotech
LLC does not accept any responsibility for possible consequences of errors
or omissions in the provided information. There is no warranty that the
information contained herein is error free. Users of this service are
advised to seek professional advice and independent confirmation before
acting on any of the provided information. thinkBiotech LLC reserves the
right to amend, extend or withdraw any part or all of the offered service
without notice.
All trademarks and applicant names are the property
of their respective owners or licensors.


Drug Patent Expirations for November 27 2014

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Journal of Commercial Biotechnology

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for November 27 2014

Tradename Applicant Generic Name Patent
Expiration
NEXIUM

Astrazeneca

esomeprazole magnesium

Nov 27, 2014
NEXIUM IV

Astrazeneca

esomeprazole sodium

Nov 27, 2014
VIMOVO

Horizon Pharma

esomeprazole magnesium; naproxen

Nov 27, 2014

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch database for
complete details.





Instant Access to Deep Knowledge on Small-Molecule
Drugs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data
    export
  • More…

More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.

See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch database for
complete details

DISCLAIMER:
Although great care
is taken in the proper and correct provision of this service, thinkBiotech
LLC does not accept any responsibility for possible consequences of errors
or omissions in the provided information. There is no warranty that the
information contained herein is error free. Users of this service are
advised to seek professional advice and independent confirmation before
acting on any of the provided information. thinkBiotech LLC reserves the
right to amend, extend or withdraw any part or all of the offered service
without notice.
All trademarks and applicant names are the property
of their respective owners or licensors.


Drug Patent Expirations for November 18 2014

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Journal of Commercial Biotechnology

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for November 18 2014

Tradename Applicant Generic Name Patent
Expiration
ALLEGRA

Sanofi Aventis Us

fexofenadine hydrochloride

Nov 18, 2014
ALLEGRA ALLERGY

Sanofi Aventis Us

fexofenadine hydrochloride

Nov 18, 2014
ALLEGRA HIVES

Sanofi Aventis Us

fexofenadine hydrochloride

Nov 18, 2014
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

Sanofi Aventis Us

fexofenadine hydrochloride; pseudoephedrine
hydrochloride

Nov 18,
2014
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

Sanofi Aventis Us

fexofenadine hydrochloride; pseudoephedrine
hydrochloride

Nov 18,
2014
CELLCEPT

Roche Palo

mycophenolate mofetil

Nov 18, 2014
CHILDREN’S ALLEGRA ALLERGY

Sanofi Aventis Us

fexofenadine hydrochloride

Nov 18, 2014
CHILDREN’S ALLEGRA HIVES

Sanofi Aventis Us

fexofenadine hydrochloride

Nov 18, 2014

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch database for
complete details.





Instant Access to Deep Knowledge on Small-Molecule
Drugs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data
    export
  • More…

More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.

See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch database for
complete details

DISCLAIMER:
Although great care
is taken in the proper and correct provision of this service, thinkBiotech
LLC does not accept any responsibility for possible consequences of errors
or omissions in the provided information. There is no warranty that the
information contained herein is error free. Users of this service are
advised to seek professional advice and independent confirmation before
acting on any of the provided information. thinkBiotech LLC reserves the
right to amend, extend or withdraw any part or all of the offered service
without notice.
All trademarks and applicant names are the property
of their respective owners or licensors.


Unlocking the Mystery of Angel Investment

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. In the “Mystery of Capital,” Peruvian economist Hernando de Soto famously writes about the need to convert assets into capital for creation of social and economic value in […]


Drug Patent Expirations for November 17 2014

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

BiologicPatentWatch -- biologic drug patent expiration information

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for November 17 2014

Tradename Applicant Generic Name Patent
Expiration
FOSAMAX

Merck

alendronate sodium

Nov 17, 2014
FUZEON

Roche

enfuvirtide

Nov 17, 2014
SURFAXIN

Discovery Labs

lucinactant

Nov 17, 2014

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.





Instant Access to Deep Knowledge on Small-Molecule
Drugs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data
    export
  • More…

More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.

See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.